Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

doi:10.1016/j.jtho.2025.11.018

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2026

Burns Timothy F, Ammakkanavar Natraj Reddy, Hollebecque Antoine, Lee Dae Ho, Koyama Takafumi, Cassier Philippe A, Italiano Antoine, Han Ji-Youn, Singhal Nimit, Takeuchi Shinji, Heist Rebecca S, Deming Dustin, Spira Alexander, Chu Quincy, Sacher Adrian, Fujiwara Yutaka, Chisamore Michael J, You Arthur Xintian, McNeely Samuel C, Fink Aaron, Chen Aaron, Oxnard Geoffrey R, Willard Melinda D, Murciano-Goroff Yonina R, Dragnev Konstantin H

Abstract excerpt

INTRODUCTION: Immunotherapy-based regimens are the standard first-line treatment for KRAS G12C-mutant NSCLC, but outcomes remain suboptimal. Prior attempts to combine KRAS G12C inhibitors with immunotherapy have been challenged by toxicity. We report results from LOXO-RAS-20001, a phase 1/2 trial evaluating the combination of olomorasib with pembrolizumab in KRAS G12C-mutant NSCLC, including in first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 41319864
DOI: 10.1016/j.jtho.2025.11.018

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.PMID 41319864Read ↗

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.Semantic proximity Read ↗

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.Semantic proximity Read ↗

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models.Semantic proximity Read ↗

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.Semantic proximity Read ↗

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.Semantic proximity Read ↗

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.Semantic proximity Read ↗

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.Semantic proximity Read ↗

KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis.Semantic proximity Read ↗

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.